Arcus Biosciences (RCUS) COO Jarrett sold 50,292 shares for $750K at an average $14.92 under a 10b5-1 plan
Insider transactions reported
Jennifer Jarrett (Chief Operating Officer at Arcus Biosciences Inc., RCUS) reported that they sold 50,292 shares for $750K at an average $14.92, and acquired 50,292 shares at $1.23 between Oct 6, 2025 and Oct 8, 2025. After these transactions the filing shows 214,232 shares held directly.
- Reporting person
- Jarrett Jennifer
- Role
- Chief Operating Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 6, 2025 | Exercise or conversion of a derivative (M) | Common Stock1, 2 | +12,500 | $1.23 | $15.3K | 226,732 direct |
| Oct 6, 2025 | Open-market sale (S) | Common Stock1, 2, 3 | -12,500 | $14.54 | $182K | 214,232 direct |
| Oct 8, 2025 | Exercise or conversion of a derivative (M) | Common Stock1, 2 | +37,792 | $1.23 | $46.4K | 252,024 direct |
| Oct 8, 2025 | Open-market sale (S) | Common Stock1, 2, 4 | -37,792 | $15.05 | $569K | 214,232 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 6, 2025 | Exercise or conversion of a derivative (M) | Stock Option (Right to Buy)On 12,500 Common Stock1, 5 | -12,500 | - | - | 168,666 direct |
| Oct 8, 2025 | Exercise or conversion of a derivative (M) | Stock Option (Right to Buy)On 37,792 Common Stock1, 5 | -37,792 | - | - | 130,874 direct |
Holdings before and after
- Stock Option (Right to Buy): 181,166 to 130,874 direct
Footnotes from the filing
- 1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan.
- 3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 5. The option is fully vested and currently exercisable.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Jarrett report in this RCUS Form 4?
Jennifer Jarrett (Chief Operating Officer at Arcus Biosciences Inc., RCUS) reported that they sold 50,292 shares for $750K at an average $14.92, and acquired 50,292 shares at $1.23 between Oct 6, 2025 and Oct 8, 2025. After these transactions the filing shows 214,232 shares held directly.
How many RCUS shares does Jarrett hold after this filing?
The filing shows 214,232 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this RCUS insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for RCUS
Earlier insider filings at RCUS
- Sep 30, 2025Chief Accounting Officer Azoy Alexander sold $36,803 worth of shares (2,831 units at $13.00), decreasing direct ownership by 9% to 27,363 units (SEC Form 4)
- Sep 5, 2025Chief Accounting Officer Azoy Alexander sold $18,758 worth of shares (1,579 units at $11.88), decreasing direct ownership by 5% to 30,194 units (SEC Form 4)
- Jun 12, 2025Director Perlman Andrew J was granted 13,300 shares, increasing direct ownership by 45% to 42,625 units (SEC Form 4)
- Jun 12, 2025Director Falberg Kathryn E was granted 13,300 shares, increasing direct ownership by 24% to 68,600 units (SEC Form 4)
- Jun 12, 2025Director Machado Patrick was granted 13,300 shares, increasing direct ownership by 53% to 38,600 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Follow RCUS and get a push notification the moment its next story breaks.